Abingdon, United Kingdom
Abingdon, United Kingdom

Time filter

Source Type

Patent
Immunocore and Adaptimmune | Date: 2016-09-12

The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs may consist essentially of TCRs which may comprise an alpha chain variable domain from a natural repertoire and a beta chain variable domain from a natural repertoire, wherein the alpha chain variable domain may comprise a TRAV12-2 or a TRAV21 gene product and the beta chain variable domain may comprise a TRBV6 gene product.


Patent
Immunocore | Date: 2017-01-04

A bifunctional polypeptide comprising a specific binding partner for a peptide-MHC epitope, such as an antibody or a T cell receptor (TCR), and an immune effector, such as an antibody or a cytokine, the immune effector part being linked to the N-terminus of the peptide-MHC binding part.


Patent
Immunocore | Date: 2017-01-04

A bifunctional polypeptide comprising a specific binding partner for a peptide-MHC epitope, such as an antibody or a T cell receptor (TCR), and an immune effector, such as an antibody or a cytokine, the immune effector part being linked to the N-terminus of the peptide-MHC binding part.


Patent
Immunocore and Adaptimmune | Date: 2017-01-18

The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs consists essentially of TCRs comprising an alpha chain variable domain from a natural repertoire and a beta chain variable domain from a natural repertoire, wherein the alpha chain variable10 domain comprises a TRAV12-2 or a TRAV21 gene product and the beta chain variable domain comprises a TRBV6 gene product.


Patent
Adaptimmune and Immunocore | Date: 2014-04-09

A proteinaceous particle, for example a bacteriophage, ribosome or cell, displaying on its surface a T-cell receptor (TCR). The displayed TCR is preferably a heterodimer having a non-native disulfide bond between constant domain residues. Such display particles may be used for the creation of diverse TCR libraries for the identification of high affinity TCRs. Several high affinities are disclosed.


Patent
Immunocore and Adaptimmune | Date: 2016-02-17

The present invention provides TCRs having an affinity (K_(D)) of less than or equal to 1M, and/or an off-rate (k_(off)) of 1x10^(-3) S^(-1) or slower, for the SLYNTVATL-HLA-A*0201 complex PROVIDED THAT when the said TCR is presented by cell and comprises SEQ ID NOs: 1 and 2, the cell is not a native T cell. Such TCRs are useful, either alone or associated with a therapeutic agent, for targeting HIV infected cells presenting that complex.


The present invention provides a T cell receptor (TCR) having the property of binding to ALWGPDPAAA (derived from human pre-pro insulin (PPI) protein) HLA-A*02 complex and comprising a TCR alpha chain variable domain and a TCR beta chain variable domain. Also provided are nucleic acids encoding the TCR and cells engineered to present the TCR. Therapeutic agents based on TCRs of the invention can be used for the purpose of delivering immunosuppressive agents to beta cells in order to prevent their destruction by CD8^(+) T cells.


The invention provides a method for predicting whether a binding peptide, which binds to a target peptide presented by a Major Histocompatibility Complex (MHC) and is for administration to a subject, has the potential to cross react with another peptide in the subject in vivo. The method comprises the steps of identifying at least one binding motif in the target peptide to which the binding peptide binds; and searching for peptides that are present in the subject that comprise the at least one binding motif and that are not the target peptide. The presence of one or more such peptides indicates that the binding peptide has the potential to cross react in vivo.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 2.40M | Year: 2013

Immunocore has developed a new class of biologic drug called ImmTACs. ImmTACs are highly novel because they recognise intracellular changes in cancerous cells and can therefore be used to treat diseases, such as prostate cancer, that are not currently ammenable to targeted biological therapies. Targeted therapies represent a significant advance over traditional chemotherapy because they selectively attack the cancer and not the rest of the body. This project is for the development of a new ImmTAC suitable for use in prostate cancer and will culminate in testing the safety and efficacy of this targeted therapy in patients with prostate cancer.


Patent
Immunocore | Date: 2016-02-08

The present invention relates to T cell receptors (TCRs) which bind the HLA-A2 restricted CLGGLLTMV peptide (SEQ ID NO: 1) derived from the LMP2A protein from Epstein Barr Virus (EBY). TCRs of the invention comprise a TCR alpha chain variable domain and/or a TCR beta variable domain. Certain preferred TCRs also bind the natural peptide variants SLGGLLTMV (SEQ ID NO: 17) and CLGGLITMV (SEQ ID NO: 18) presented as a peptide-HLA-A2 complex. The TCRs of the invention demonstrate excellent specificity profiles for those LMP2A epitopes and have binding affinities for the complex which result in an enhanced ability to recognize the complex compared to a soluble reference TCR having the extracellular sequence of the native EBY LMP2A TCR alpha chain given in FIG. 3 (SEQ ID No: 4) and the extracellular sequence of the native EBY LMP2A TCR beta chain given in FIG. 4 (SEQ ID No: 5).

Loading Immunocore collaborators
Loading Immunocore collaborators